How Has the Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market Size Evolved in Recent Years?
The alpha 1 antitrypsin deficiency augmentation therapy market has seen considerable growth due to a variety of factors.
• The market size of alpha-1 antitrypsin deficiency augmentation therapy has witnessed significant growth in the past few years. It is expected to increase from $1.69 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%.
Factors such as enhanced diagnostic methods, awareness initiatives, clinical studies, and an ageing population have contributed to the growth during the historic period.
What Are The Predictions for The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market in the Coming Years?
The alpha 1 antitrypsin deficiency augmentation therapy market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipating a significant expansion in the forthcoming years, the market size of alpha-1 antitrypsin deficiency augmentation therapy is predicted to reach $2.47 billion in 2029, following a compound annual growth rate (CAGR) of 7.9%.
The surge during the forecast period can be linked to the rise in telehealth and remote monitoring, enhancement in precision medicine, as well as progresses in gene therapy. The prognosis period also coincides with major trends like the presentation of long-term safety and efficiency data, adoption of patient-centric care models, implementation of tele-rehabilitation programs, and the development of personalized dosing plans.
Which Drivers Are Accelerating Growth In The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market?
The alpha-1 antitrypsin deficiency augmentation therapy market's expansion is being driven by a surge in respiratory illnesses. Respiratory diseases are conditions that impact the lungs and the respiratory system, causing breathing issues and compromising lung functionality. Alpha-1 antitrypsin deficiency augmentation therapy is designed to address respiratory diseases by providing the missing protein in those suffering from alpha-1 antitrypsin deficiency. This therapy rebalances protease-antiprotease activity in the lungs, shields lung tissue from harm caused by excessive neutrophil elastase activity, and reduces inflammation. For instance, the Centers for Disease Control and Prevention reported that in the United States, tuberculosis (TB) cases rose to 8,300 in March 2023 from 7,874 in 2021, marking an increase. Consequently, the surge in respiratory illnesses is accelerating the alpha-1 antitrypsin deficiency augmentation therapy market's growth. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Driver: The expected increase in clinical trials may inject momentum into the alpha-1 antitrypsin deficiency augmentation therapy market.
What Are The Core Segments Of The Global Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
Pre-Book The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market?
Leading businesses in the acute respiratory distress syndrome (ARDS) market are emphasizing on the development of novel therapies like recombinant technology-based drug development to maintain their market dominance. The recombinant DNA technique, often used for creating pharmaceutical therapeutics using recombinant technology-based drug development, involves altering the DNA of living organisms to produce specific proteins. As an illustration, Inhibrx Inc., an American biotech firm, stated in March 2022 that the U.S. Food and Drug Administration (FDA) had granted INBRX-101, a recombinant human AAT-Fc fusion protein, an orphan drug status for the treatment of alpha-1 antitrypsin deficiency (AATD). Required possibly just once a month, INBRX-101 seeks to safely realize and sustain the AAT levels identifiable in healthy individuals.
Who Are the Key Players In The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are:
• Pfizer Inc.
• Sanofi S.A.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Baxter International Inc.
• CSL Limited
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Grifols S.A.
• BioMarin Pharmaceutical Inc.
• LFB Group
• Octapharma AG
• Arrowhead Pharmaceuticals Inc.
• Kamada Ltd.
• Krystal Biotech Inc.
• Intellia Therapeutics Inc.
• Mereo BioPharma Group PLC
• Protalix BioTherapeutics Inc.
• Centessa Pharmaceuticals Limited
• Inhibrx Inc.
• Liminal BioSciences Inc.
• Applied Genetic Technologies Corporation
• Abeona Therapeutics Inc.
What Are The Regional Insights Into The Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
